Successful conduct of an acute stroke clinical trial during COVID.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
29
10
2020
accepted:
24
11
2020
entrez:
15
1
2021
pubmed:
16
1
2021
medline:
22
4
2021
Statut:
epublish
Résumé
Most clinical research stopped during COVID due to possible impact on data quality and personnel safety. We aimed to assess the impact of COVID on acute stroke clinical trial conduct at sites that continued to enroll patients during the pandemic. BEST-MSU is an ongoing study of Mobile Stroke Units (MSU) vs standard management of tPA-eligible acute stroke patients in the pre-hospital setting. MSU personnel include a vascular neurologist via telemedicine, and a nurse, CT technologist, paramedics and emergency medicine technicians on-board. During COVID, consent, 90-day modified Rankin Scale (mRS) and EQ5D were obtained by phone instead of in-person, but other aspects of management were similar to the pre-COVID period. We compared patient demographics, study metrics, and infection of study personnel during intra- vs pre-COVID eras. Five of 6 BEST-MSU sites continued to enroll during COVID. There were no differences in intra- (n = 57) vs pre- (n = 869) COVID enrolled tPA eligible patients' age, sex, race (38.6% vs 38.0% Black), ethnicity (15.8% vs 18.6% Hispanic), or NIHSS (median 11 vs 9). The percent of screened patients enrolled and adjudicated tPA eligible declined from 13.6% to 6.6% (p < .001); study enrollment correlated with local stay-at-home and reopening orders. There were no differences in alert to MSU arrival or arrival to tPA times, but MSU on-scene time was 5 min longer (p = .01). There were no differences in ED door to CT, tPA treatment or thrombectomy puncture times, hospital length of stay, discharge disposition, or remote vs in-person 90-day mRS or EQ5D. One MSU nurse tested positive but did not require hospitalization. Clinical research in the pre-hospital setting can be carried out accurately and safely during a pandemic. tPA eligibility rates declined, but otherwise there were no differences in patient demographics, deterioration of study processes, or serious infection of study staff. Trial registration: NCT02190500.
Identifiants
pubmed: 33449944
doi: 10.1371/journal.pone.0243603
pii: PONE-D-20-34076
pmc: PMC7810330
doi:
Substances chimiques
Tissue Plasminogen Activator
EC 3.4.21.68
Banques de données
ClinicalTrials.gov
['NCT02190500']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0243603Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Stroke Cerebrovasc Dis. 2020 Oct;29(10):105114
pubmed: 32912527
Stroke. 2017 Feb;48(2):493-496
pubmed: 28082671
Trials. 2020 Sep 11;21(1):784
pubmed: 32917258
Neurol Int. 2013 Feb 19;5(1):e2
pubmed: 23717781
Int J Stroke. 2018 Apr;13(3):321-327
pubmed: 28612680
Nat Rev Cardiol. 2020 Nov;17(11):673-675
pubmed: 32873977
Stroke. 2018 Jun;49(6):1528-1530
pubmed: 29720439
Stroke. 2019 Dec;50(12):e344-e418
pubmed: 31662037
Restor Neurol Neurosci. 2015;33(5):771-5
pubmed: 26410209
Stroke. 2020 Sep;51(9):2664-2673
pubmed: 32755347